Generic placeholder image

Current Angiogenesis (Discontinued)


ISSN (Print): 2211-5528
ISSN (Online): 2211-5536

Targeting Angiogenesis in Thyroid Cancer

Author(s): S. Lkhoyaali, S. Benhmida, M. Aitelhaj, M. Layachi, H. Abahssain, H.N. Ismaili and H. Errihani

Volume 3, Issue 2, 2014

Page: [107 - 112] Pages: 6

DOI: 10.2174/2211552802666140716170521

Price: $65


Thyroid cancers are characterized by a good prognosis but 10 to 15% of patients progress and become refractory to current therapies. Systemic treatment based on chemotherapy in these settings has shown limited efficacy, with response rates not exceeding 25%. At progression, differentiated thyroid cancer is characterized by a high level of expression of vascular endothelial growth factor (VEGF). This high expression of VEGF is associated with an aggressive tumor behavior and a poor clinical outcome.

We will review the recent advances in targeting angiogenesis in the treatment of recurrent and metastatic thyroid carcinoma.

Keywords: Angiogenesis, targeted therapy, thyroid cancer.

Next »
Graphical Abstract

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy